Langley RG, et al. - A scrutiny was carried out of the safety profile and efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis who responded inadequately to ustekinumab. The most commonly reported adverse event with guselkumab or ustekinumab was found to be infections. A shift to guselkumab could prove to be effective in individuals who did not achieve clear or almost clear skin after ustekinumab treatment. Treatment with guselkumab did not raise safety concerns.